It has been a good week for CSL Behring as it rolls out haemophilia B gene therapy Hemgenix, with positive reimbursement decisions in both the UK and Denmark. In the UK, health technology ...

Investing.com -- Global biotechnology leader CSL Behring (ASX:CSL ... for the European Union and European Economic Area, the UK's Medicines and Healthcare products Regulatory Agency (MHRA ...

I maintain a Neutral view on CSL Limited due to the mixed prospects for its flu vaccine (Seqirus) and plasma therapy (Behring ...

This includes an estimated 8% growth for the CSL Behring division and around 3% for both the Seqirus and Vifor divisions. The initiation of coverage with an Overweight rating and a substantial price ...

The drug has also been approved in the UK and Australia to date and is under ... It will be launched in the EU by the company's CSL Behring unit upon completion of access and reimbursement ...

DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded ...

Morgan Stanley initiated coverage of CSL (CSLLY) with an Overweight rating and A$313 price target A “solid revenue growth outlook” and margin ...

CSL Behring KK has gained approval from Japan's ... The latest approval follows authorisations in the European Union, Australia and the UK. CSL research and development for Japan and China ...

For more than a century, CSL Behring has earned a reputation as an organization driven to care for patients with rare and serious diseases. We are a company known for keeping our promises – to ...